Premium
Poor outcomes for double‐hit lymphoma patients treated with curative‐intent second‐line immunochemotherapy following failure of intensive front‐line immunochemotherapy
Author(s) -
Landsburg Daniel J.,
Ayers Emily C.,
Bond David A.,
Maddocks Kami J.,
Karmali Reem,
Behdad Amir,
Curry Madeira,
WagnerJohnston Nina D.,
Modi Dipenkumar,
Ramchandren Radhakrishnan,
Assouline Sarit E.,
Faramand Rawan,
Chavez Julio C.,
Torka Pallawi,
Mier Hicks Angel,
Medeiros L. Jeffrey,
Li Shaoying
Publication year - 2020
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.16319
Subject(s) - medicine , front line , second line , oncology , refractory (planetary science) , lymphoma , progression free survival , overall survival , salvage therapy , first line , chemotherapy , physics , astrobiology , political science , law
Summary While patients with double‐hit lymphoma (DHL) are now frequently treated with intensive front‐line immunochemotherapy, outcomes for those who fail these regimens and subsequently receive curative‐intent second‐line immunochemotherapy are unknown. We identified 55 such patients who achieved an overall/complete response rate of 29%/11%, median progression‐free/overall survival (PFS/OS) of 2/5·1 months and one‐year PFS/OS of 10/19% following the start of second‐line therapy. These outcomes may serve as a standard against which future second‐line treatment strategies for relapsed/refractory DHL can be measured and justify investigation of non‐cytotoxic therapies in the second‐line setting for these patients.